相关实验视频

Updated: Mar 11, 2026

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique
06:47

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Published on: September 20, 2011

38.4K

配方设计,优化和Palbociclib载入的聚合物纳米粒子的In Vitro评估

Nurjamal Hoque1, Ananta Choudhury1

  • 1Faculty of Pharmaceutical Science, Assam down town University, Guwahati, Assam, India.

Assay and drug development technologies
|March 10, 2026
PubMed
概括

这项研究开发了叶酸修饰的奇托桑纳米颗粒,用于乳腺癌中提供palbociclib. 这些纳米颗粒提供受控的,pH响应的药物释放,增强治疗潜力.

关键词:
基托桑纳米颗粒是一种纳米粒子.药物释放反应于pH的药物释放.这是palbocicliblib.表面分析 表面分析瘤微环境是一个微环境.

更多相关视频

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles07:32

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles

Published on: August 28, 2015

12.1K
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

9.5K

相关概念视频

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
71
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
211